Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma

Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma
Graphical abstract:Constitutively activated Gαq/11 proteins drive the vast majority of uveal melanoma (UM). GQ262 effectively combats UM both in vitro and in vivo by targeting Gαq/11 directly. Credit: Acta Pharmaceutica Sinica B (2022). DOI: 10.1016/j.apsb.2022.04.016

Constitutively activated G proteins caused by specific mutations mediate the development of multiple malignancies. The mutated Gαq/11 are perceived as oncogenic drivers in the vast majority of uveal melanoma (UM) cases, making directly targeting Gαq/11 to be a promising strategy for combating UM.

In this article, the authors report the optimization of imidazopiperazine derivatives as Gαq/11 and identified GQ262 with improved Gαq/11 inhibitory activity and drug-like properties. GQ262 efficiently blocked UM cell proliferation and migration in vitro. Analysis of the apoptosis-related proteins, extracellular signal-regulated kinase (ERK), and yes-associated protein (YAP) demonstrated that GQ262 distinctly induced UM cells apoptosis and disrupted the downstream effectors by targeting Gαq/11 directly. Significantly, GQ262 showed outstanding antitumor efficacy in vivo with good safety at the testing dose.

These findings along with the favorable pharmacokinetics of GQ262 suggest that directly targeting Gαq/11 may be an efficient strategy against .

The research was published in Acta Pharmaceutica Sinica B.

More information: Yang Ge et al, Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma, Acta Pharmaceutica Sinica B (2022). DOI: 10.1016/j.apsb.2022.04.016

Provided by Compuscript Ltd
Citation: Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma (2022, September 5) retrieved 4 February 2023 from https://medicalxpress.com/news/2022-09-discovery-small-molecule-gq11-protein.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation

11 shares

Feedback to editors